What Koru Pharma does

Koru Pharma Co., Ltd. is a South Korea-based B2B medical aesthetics company that develops, manufactures, and exports a portfolio of dermal fillers, mesotherapy and skin booster solutions, collagen biostimulators, exosome-based regenerative products, and hair restoration treatments. Its three anchor proprietary platforms are MCO® (an optimized HA cross-linking chemistry powering the AVALON™ filler line), ACAPLEX™ (a KORU-ACA01 peptide combined with bio-identical Type III collagen powering MESOHEAL® Bio), and HALOS™ (a multi-pathway technology powering the H Bloom AHL hair line), supplemented by patent-secured BDDE-free and HA-agarose filler chemistries. Manufacturing runs from a 1,800 sqm Korean facility with 3 million syringes per annum capacity, supported by an R&D laboratory in Chuncheon and a Gangnam-district headquarters.

The company sells exclusively B2B to licensed aesthetic professionals (physicians, dermatologists, plastic surgeons, trichologists) and medical spas through direct field sales and authorized distributors, reaching 100+ countries. Go-to-market is event-driven, anchored by participation in AMWC Monaco, IMCAS, Dubai Derma, and CIBE Guangzhou, combined with Koru Academy webinars and a network of 15+ international KOL advocates. Revenue mechanics are one-time product sales at undisclosed list pricing, with quotes negotiated by order volume and geography. The company has secured CE MDR (Avalon Fine/Vital), MDSAP, Russian Federation healthcare approval, and EUIPO AVALON trademark, and has publicly signaled intent to pursue an IPO, with LYFE Capital and KB Investment disclosed as strategic capital partners.

Name

Koru Pharma

Legal name

Koru Pharma Co., LTD

Website

https://korupharma.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

51–100 employees

Short description

Koru Pharma is a Seoul-based B2B medical aesthetics company that develops and manufactures dermal fillers, skin boosters, biostimulators, exosome products, and hair restoration treatments for licensed clinicians in 100+ countries.

Ownership category

akta.pro rank

Product category

Medical Aesthetic Injectables

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Perfumes, Cosmetics & Other Toilet Preparations (2844), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

akta.pro secondary industries

Dermocosmetics & Medical-Grade Skincare (CRABAAAF), Treatment Skincare (Serums, Actives, Acne & Anti-aging) (CRABAAAB), Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Professional/Backbar Skincare (Esthetician & Spa Use) (CRABAAAK)

Keywords

• Medical aesthetic injectables
• Hyaluronic acid fillers
• Skin booster mesotherapy
• Collagen biostimulators
• Hair restoration treatments

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Supply Chain, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Medical Aesthetic Products: Koru Pharma generates revenue through the sale of medical aesthetic products including dermal fillers (AVALON™), mesotherapy solutions (MESOHEAL® series), skin boosters (Crystal Healer, Renoxome), biostimulators (REVERSAL series), and hair restoration products (H Bloom). The company sells directly to healthcare professionals, clinics, and medical spas on a B2B basis.

Go-to-market motion3 records

Distribution channels1 record

Marketing channels6 records

Core offering

Koru Pharma develops and manufactures a portfolio of injectable medical aesthetic products — hyaluronic acid dermal fillers (AVALON™), skin boosters and mesotherapy solutions (MESOHEAL® series, Crystal Healer PN/NMN), collagen biostimulators (REVERSAL Neo/Dual/Shape), exosome-based skin boosters (Renoxome+), wrinkle reducers (ELITOX®), and hair restoration treatments (H Bloom, H Bloom AHL) — and sells them B2B to licensed healthcare professionals, clinics, and medical spas in over 100 countries.

Product overview

Koru Pharma is a global aesthetics company specializing in advanced bio-technologies for anti-aging and medical aesthetic solutions. The portfolio consists of three main product categories: dermal fillers (AVALON™ Fillers for facial contouring, MESOHEAL® Body HA for body contouring), skinboosters/biostimulators (MESOHEAL® Bio with ACAPLEX™, MESOHEAL® Phlo with HA+PN, Crystal Healer NMN with NMN/PDRN, Crystal Healer PN Series, Renoxome exosome products, REVERSAL Neo/Dual/Shape PLLA-based products), and hair restoration (H Bloom and H Bloom AHL with proprietary peptides). Core proprietary technologies include MCO® Tech for optimized HA cross-linking, ACAPLEX™ for peptide-collagen regeneration, and HALOS™ for multi-pathway hair treatment. The company operates Koru Academy as an educational platform for practitioner training.

Differentiator

Problem solved

Functional benefit

Brands

• AVALON™ Fillers: Non-animal origin stabilised hyaluronic acid fillers for correction of wrinkles and lines, restoration of volume loss, lip augmentation, and correction of face contours.
• MESOHEAL® Glow Series
• Crystal Healer PN Series
• H Bloom
• H Bloom AHL
• Reversal
• Renoxome
• MESOHEAL® Phlo
• Crystal Healer NMN
• MESOHEAL® Bio
• MESOHEAL® Body Fillers
• MCO® Tech
• ACAPLEX™
• Koru Academy

Products and services

• AVALON™ Fillers Non-animal origin stabilised hyaluronic acid dermal fillers for correction of wrinkles and lines of different depths, restoration of volume loss, lip augmentation, and correction of face contours. Powered by MCO® cross-linking technology. Marketed to aesthetic physicians, dermatologists, and plastic surgeons.
• MESOHEAL® Glow Series Professional-grade skin rejuvenation and radiance products providing deep hydration and restoring skin vitality. Formulated for clinics and beauty professionals performing mesotherapy and skin quality treatments.
• Crystal Healer PN Series Advanced skin regeneration and elasticity-boost skincare solution containing polynucleotides (PN), revitalising damaged skin and achieving a youthful appearance. Designed for aesthetic practitioners performing skin rejuvenation treatments.
• H Bloom AHL Advanced multi-pathway hair and scalp health solution addressing key factors linked to hair thinning. Powered by proprietary KORU-AHL peptides and HALOS™ technology, it helps rebalance hair growth signals, supports follicle function, and optimises the scalp environment. CE certified. Targeted at trichologists and aesthetic doctors performing hair restoration treatments.
• MESOHEAL® Bio Advanced skinbooster with ACAPLEX™ technology combining KORU-ACA01 peptide and Bio-Identical Type III Collagen with 1.5% dual molecular weight non-crosslinked hyaluronic acid for deep hydration, collagen stimulation, and skin rejuvenation. Indicated for patients with photoaging, severe inflammatory conditions such as rosacea, post-acne scarring, and overall skin vitality. Targeted at aesthetic physicians and dermatologists.
• Crystal Healer NMN Dual-vial rejuvenating skinbooster combining PDRN, NMN (nicotinamide mononucleotide), and amino acids that restores cellular energy, stimulates regeneration, and enhances skin firmness, elasticity, and radiance. Designed for aesthetic professionals performing cellular anti-aging treatments.
• Reversal Neo Next-generation collagen-stimulating injectable with high-purity Poly-L-Lactic Acid (PLLA) designed for gradual, long-lasting volume restoration, skin structure improvement, and natural rejuvenation. Indicated for plastic surgeons and aesthetic physicians performing facial biostimulation.
• Reversal Dual Premium dual-vial skin booster combining Poly-L-Lactic Acid (PLLA) and Hyaluronic Acid (HA) delivering instant hydration and progressive collagen regeneration for naturally youthful, long-lasting results. Designed for professional mesotherapy.
• REVERSAL Shape Advanced PLLA-based body contouring solution for long-lasting volume restoration, skin tightening, and structural skin improvement. Stimulates the body's natural collagen production for gradual, natural-looking enhancement in body areas. Targeted at plastic surgeons and aesthetic physicians performing non-surgical body contouring.
• MESOHEAL® Phlo Premium skin booster with dual molecular weight hyaluronic acid (4%) and polynucleotides (PN) delivering deep hydration, skin renewal, and improved texture, tone, and elasticity with minimal downtime. Indicated for professional skin rejuvenation protocols.
• MESOHEAL® Body HA Fillers Highly purified viscoelastic hyaluronic acid body fillers for replenishing body volume and professional contouring of areas including abdomen, lower back, hips, thighs, buttocks, and upper arms. Available in 50ml format. Targeted at plastic surgeons and aesthetic physicians performing body contouring.
• Renoxome+ Exosome-based skin booster for deep healing and advanced skin regeneration, part of the Renoxome Line supporting barrier recovery, collagen stimulation, and improved skin resilience. Targeted at aesthetic practitioners performing regenerative skin treatments.
• ELITOX® Series Series of injectables designed for safe and effective wrinkle reduction, used by aesthetic physicians and dermatologists in facial aesthetic procedures.

Quantifiable outcome

• 3 million syringes per annum manufacturing capacity
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators5 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Evolus: US-based aesthetics company focused on premium injectable neurotoxins (Jeuveau) with a growth-stage profile. Comparable as a newer, innovation-driven player targeting physician channels in the medical aesthetics space.
• Teoxane: Swiss aesthetics company specializing in HA dermal fillers (Teosyal range) and cosmeceuticals. Closely comparable to Koru as a focused, IP-driven filler specialist with global distribution and premium positioning.
• Sinclair Pharma: Aesthetic medicine specialist offering HA fillers (MaiLi), biostimulators (Lanluma PLLA), and complementary portfolio. Comparable mid-cap challenger with similar global distribution strategy.
• IBSA Farmaceutici: Italian pharma company with Profhilo (hybrid HA complex), a leading skin booster franchise. Direct comparable to Koru's MESOHEAL and Crystal Healer skin booster lines, with similar B2B medical-channel distribution.
• Croma-Pharma: Austrian aesthetics company with a HA filler portfolio, PLLLA-based bio-stimulators, and a growing international footprint. Comparable mid-sized challenger competing against incumbent filler giants.

Broad incumbents

• AbbVie (Allergan Aesthetics): Owns the Juvéderm HA filler franchise, BOTOX, and CoolSculpting — the dominant aesthetics portfolio globally. Competes with Koru across facial fillers, biostimulators, and body contouring, with far greater sales/marketing scale.
• Galderma: Global dermatology and aesthetics leader owning Restylane (HA filler), Sculptra (PLLA biostimulator), and a comprehensive portfolio across facial aesthetics. Directly competes with Koru's AVALON fillers and Reversal PLLA products, but at vastly larger scale.
• Merz Aesthetics: Sells Belotero (HA filler), Radiesse (CaHA biostimulator), and Xeomin. Direct competitor to Koru's AVALON fillers and Reversal PLLA products, with established global distribution and physician relationships.

Regional players

• Hugel: South Korean aesthetics company producing botulinum toxin (Botulax), HA fillers, and biostimulators. Directly comparable regional peer with overlapping product categories and similar target markets in Asia.
• LG Chem (Life Sciences): Korean conglomerate with a Life Sciences division producing aesthetic dermatology products including HA fillers (Yvoire) and botulinum toxin. Comparable South Korean peer with similar product mix and export ambitions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/KoruPharma
• Facebookfacebook.com/KoruPharmaOfficial
• LinkedInlinkedin.com/company/korupharma

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Koru Pharma